Compare Novavax Inc (NVAX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Twist Bioscience Corp — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Twist Bioscience Corp is far larger — about 4.2× Novavax Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | TWST | |
|---|---|---|
Market Cap | $1.30B | $5.45B |
Sector | Health | Health |
52-Week High | $11.19 | $102.88 |
52-Week Low | $6.22 | $24.16 |
Enterprise Value | $800.50M | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
